GSK reported good clinical trial results with two of its lung cancer therapies – Jideytro and risvutatug rezetecan (ris-rez) ...

The Danish Group stated that the new corporate culture – dubbed 'The Novo Way' – centres around four Cs; namely, customer ...

Etcamah is already approved in the US, Europe, and other markets for use in combination with a CDK4/6 inhibitor as a ...

The offer is legally conditioned upon the private equity company's Respighi BidCo vehicle securing at least a two-thirds ...

HHS has moved to firm up the leadership at the FDA after a long period of uncertainty and disruption, upgrading the heads of the agency's centres governing drugs and biologics from acting to permanent ...

Hard on the heels of a big disappointment in its cardiovascular pipeline, Novartis has suffered another – this time for its highly anticipated neuromuscular disease therapy del-desiran. The company's ...

Jiangsu Hengrui Pharma's oral thrombopoietin (TPO) receptor agonist hetrombopag has been approved in China to treat low ...

Right after reporting encouraging data with its Dravet syndrome gene therapy, Encoded Therapeutics has raised an impressive ...

The pivotal QUINTESSENTIAL trial of the potentially first-in-class CAR-T showed a "statistically significant and clinically ...

Amgen's fast-growing cancer immunotherapy Imdelltra could move into the first-line setting in small cell lung cancer (SCLC), ...

Gilead's twice-yearly injectable for pre-exposure prophylaxis (PrEP) of HIV, lenacapavir, will not be routinely funded by the ...